3-氨基-4-羟基吡啶盐酸盐 | 401566-69-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氨基-4-羟基吡啶盐酸盐
• 中文别名: 5,6-二氯烟酸乙酯；乙基5,6-二氯吡啶-3-羧酸
• 英文名称: ethyl 5,6-dichloronicotinate
• 英文别名: ethyl 5,6-dichloropyridine-3-carboxylate
• CAS: 401566-69-6
• 化学式: C₈H₇Cl₂NO₂
• mdl: MFCD03093627
• 分子量: 220.055
• InChiKey: WGQSPCCCBKQNEV-UHFFFAOYSA-N

物化性质

• 熔点：
  46°C
• 沸点：
  281.3±35.0 °C(Predicted)
• 密度：
  1.367±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 储存条件：
  室温

SDS

---

Section I.Chemical Product and Company Identification
Chemical Name 5,6-Dichloronicotinic Acid Ethyl Ester
Portland OR
Synonym Ethyl 5,6-Dichloropyridine-3-carboxylate
Chemical Formula C8H7Cl2NO2
CAS Number Not available.

---

Section II. Composition and Information on Ingredients
Chemical Name CAS Number Percent (%) TLV/PEL Toxicology Data
5,6-Dichloronicotinic Acid Ethyl Ester Not available. ---------- Not available. Not available.

---

Section III. Hazards Identification
Acute Health Effects Irritating to eyes and skin on contact. Inhalation causes irritation of the lungs and respiratory system. Inflammation of the
eye is characterized by redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening,
or, occasionally, blistering.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
CARCINOGENIC EFFECTS : Not available.
Chronic Health Effects
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.

---

Section IV. First Aid Measures
Eye Contact Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Get medical attention.
Skin Contact In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing
before reuse. Thoroughly clean shoes before reuse. Get medical attention.
Inhalation If the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
Ingestion INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the
toxic material was ingested; the absence of such signs, however, is not conclusive.

---

Section V. Fire and Explosion Data
Auto-Ignition Not available.
Flammability May be combustible at high temperature.
Flammable Limits
Flash Points Not available.
Not available.
Combustion Products These products are toxic carbon oxides (CO, CO 2), nitrogen oxides (NO, NO2), halogenated compounds.
WARNING: Highly toxic HCl gas is produced during combustion.
Fire Hazards
Not available.
Explosion Hazards Risks of explosion of the product in presence of mechanical impact: Not available.
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media
SMALL FIRE: Use DRY chemical powder.
and Instructions LARGE FIRE: Use water spray, fog or foam. DO NOT use water jet.
Consult with local fire authorities before attempting large scale fire-fighting operations.
Continued on Next Page
5,6-Dichloronicotinic Acid Ethyl Ester

---

Section VI. Accidental Release Measures
Spill Cleanup Irritating Material.
Instructions Use a shovel to put the material into a convenient waste disposal container. Finish cleaning the spill by rinsing any
contaminated surfaces with copious amounts of water. Consult federal, state, and/or local authorities for assistance on
disposal.

---

Section VII. Handling and Storage
Handling and Storage IRRITANT. Keep away from heat. Mechanical exhaust required. When not in use, tightly seal the container and store in
a dry, cool place. Avoid excessive heat and light. Do not breathe dust.
Information
Always store away from incompatible compounds such as oxidizing agents.

---

Section VIII. Exposure Controls/Personal Protection
Engineering Controls Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection Splash goggles. Lab coat. Dust respirator. Boots. Gloves. Suggested protective clothing might not be sufficient; consult
a specialist BEFORE handling this product. Be sure to use a MSHA/NIOSH approved respirator or equivalent.
Exposure Limits Not available.

---

Section IX. Physical and Chemical Properties
Solubility
Physical state @ 20°C Solid. (White Crystalline Powder) Not available.
Not available.
Specific Gravity
Molecular Weight 220.05 Partition Coefficient Not available.
Boiling Point Not available. Vapor Pressure Not applicable.
Melting Point 46°C (114.8°F) Vapor Density Not available.
Not available. Volatility Not available.
Refractive Index
Critical Temperature Odor Not available.
Not available.
Not available. Not available.
Viscosity Taste

---

Section X. Stability and Reactivity Data

---

This material is stable if stored under proper conditions. (See Section VII for instructions)
Stability
Conditions of Instability
Avoid excessive heat and light.
Incompatibilities
Reactive with strong oxidizing agents.

---

Section XI. Toxicological Information
RTECS Number Not available.
Routes of Exposure Eye Contact. Ingestion. Inhalation.
Not available.
Toxicity Data
Chronic Toxic Effects CARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Not available.
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
Irritating to eyes and skin on contact. Inhalation causes irritation of the lungs and respiratory system. Inflammation of the
Acute Toxic Effects
eye is characterized by redness, watering, and itching. Skin inflammation is characterized by itching, scaling, reddening,
or, occasionally, blistering.
Follow safe industrial hygiene practices and always wear proper protective equipment when handling this compound.
Continued on Next Page
5,6-Dichloronicotinic Acid Ethyl Ester

---

Section XII. Ecological Information
Ecotoxicity Not available.
Environmental Fate Not available.

---

Section XIII. Disposal Considerations
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
Waste Disposal
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.

---

Section XIV. Transport Information
DOT Classification Not a DOT controlled material (United States).
PIN Number Not applicable.
Proper Shipping Name
Not applicable.
Packing Group (PG) Not applicable.
DOT Pictograms

---

Section XV. Other Regulatory Information and Pictograms
TSCA Chemical Inventory This product is NOT on the EPA Toxic Substances Control Act (TSCA) inventory. The following notices are required by 40
CFR 720.36 (C) for those products not on the inventory list:
(EPA)
(i) These products are supplied solely for use in research and development by or under the supervision of a technically
qualified individual as defined in 40 CFR 720.0 et sec.
(ii) The health risks of these products have not been fully determined. Any information that is or becomes available will be
supplied on an MSDS sheet.
WHMIS Classification Not available.
(Canada)
EINECS Number (EEC) Not available.
EEC Risk Statements R36/37/38- Irritating to eyes, respiratory system and skin.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氨基-4-羟基吡啶盐酸盐 在 sodium hydroxide 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 0.5h， 以91%的产率得到5,6-二氯烟酸
  参考文献：
  名称：

  N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF

  摘要：

  该发明提供了具有一般公式的新化合物：及其药用盐，其中变量RA、下标n、环A、X2、L、下标m、X1、B、R1、R2、R3、R4、R5和RN的含义如本文所述，并含有这种化合物和使用这种化合物和组合物的方法。

  公开号：

  US20130317000A1
• 作为产物：
  描述：

  乙醇 、 5,6-二氯烟酸 在 三甲基氯硅烷 作用下， 反应 72.0h， 生成 3-氨基-4-羟基吡啶盐酸盐
  参考文献：
  名称：

  [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  [FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE

  摘要：

  这项发明涉及一种式(I)的配方，或其药用可接受的盐，其中R1、R2a、R2b和R3-R7在此处。该发明还涉及含有式(I)化合物的组合物，以及在抑制具有新型活性的突变IDH蛋白中使用这种化合物的用途。该发明还涉及在治疗与这种突变IDH蛋白相关的疾病或紊乱中使用式(I)化合物，包括但不限于细胞增殖紊乱，如癌症。

  公开号：

  WO2014141104A1

文献信息

• NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES
  申请人：Bolli Martin

  公开号：US20110046170A1

  公开（公告）日：2011-02-24

  The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

  本发明涉及新颖的嘧啶-吡啶衍生物、其制备方法及其作为药理活性化合物的应用。这些化合物特别作为免疫调节剂发挥作用。
• PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS
  申请人：Bolli Martin

  公开号：US20110212998A1

  公开（公告）日：2011-09-01

  The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.

  本发明涉及式（D）的新吡啶衍生物、它们的制备方法以及它们作为药物活性化合物的用途。所述化合物特别是作为免疫调节剂发挥作用。式（I）中，A代表，其他取代基如权利要求中所定义。
• [EN] NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRIMIDINE-PYRIDINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009109907A1

  公开（公告）日：2009-09-11

  The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula I.

  本发明涉及新颖的嘧啶-吡啶衍生物、其制备方法及其作为药理活性化合物的应用。所述化合物特别作为免疫调节剂发挥作用。式I。
• [EN] PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS DE PYRROLOPYRIDINONE EN TANT QUE BLOQUANTS DES TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2013161312A1

  公开（公告）日：2013-10-31

  The present invention relates to pyrrolopyridinone derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡咯并吡啶酮衍生物，这些衍生物对TTX-S型电压门控钠通道具有阻断作用，并且在治疗或预防涉及电压门控钠通道的疾病和障碍中具有用途。发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的使用。
• COMPOUNDS
  申请人：Alemparte-Gallardo Carlos

  公开号：US20090306089A1

  公开（公告）日：2009-12-10

  Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof: (relative chemistry shown) pharmaceutical compositions comprising them, their use in therapy especially against tuberculosis, and methods of preparing them are described.

  公式(I)的化合物或其药用可接受的盐或N-氧化物，(相对化学显示)包含它们的药物组合物，它们在治疗中的用途特别是针对结核病，以及制备它们的方法被描述。